Global Brachytherapy Market Size 2020, By Application (Prostate Cancer, Gynaecological Cancer, Breast Cancer, Others), Type (High Dose-Rate Brachytherapy, Low Dose-Rate Brachytherapy), Region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa) and Forecast 2022 to 2032

Radiation therapy is deliberated the key treatment modality of malignancies, as oral cancers are proficiently treated with this modality it is vital that the kinds of radiation therapies with their history,  present and forthcoming must be known to the health care specialists. Brachytherapy procedure contains the practice of small radioactive sources sited inside the body cavity inside the tumor or nearby it. It is appropriate for management of tumors by locating the sources by means of needles or catheters. Most common brachytherapy sources give out ‘photons’, though ‘beta rays’ and ‘neutrons’ releasing sources are similarly used.

Table 1: Some commonly used radioactive sources

On the basis of type, the market is segmented into high dose-rate (HDR) brachytherapy and low dose-rate (LDR) brachytherapy. The HDR brachytherapy segment dominated the market in 2020. By appropriate case selection and transfer system, HDR brachytherapy has abundant promise, since it excludes radiation exposure, lets small treatment times, and can be executed on an outpatient base. Moreover, use of a single-stepping basis, sanctions optimization of dose delivery by changing the dwell time at every dwell location. Nevertheless, when HDR brachytherapy is used, the treatments must be performed cautiously, since the small treatment periods do not permit any time for rectification of mistakes, and errors can effect in injury to patients. Therefore, it is very essential that all staffs intricate in HDR brachytherapy be well educated and be constantly alert. It is anticipated that the use of HDR brachytherapy will critically enlarge over the subsequent decade and that modifications will happen predominantly in the incorporation of imaging and optimization of dose delivery. It is expected that improved tumor localization and normal tissue definition will aid to adjust dose distribution to the tumor and decrease normal tissue exposure.

North America accounted for the largest share of the global brachytherapy market in 2020. In the United States, the National Cancer Database (NCDB) records display that 17% of Black, 64% of Caucasian, and 14% of Hispanic patients received a brachytherapy enhancement for cervical cancer, representing racial inequalities in the reception of treatment. Probable causes for underutilization of brachytherapy for cervical cancer comprise a change to high-dose-rate (HDR) brachytherapy necessitating increased time and practice of cutting-edge imaging equipment for safe practice, greater reimbursement charges with intensity-modulated radiation therapy and stereotactic body radiation therapy, less patients having admission to brachytherapy owing to recommendation patterns, inadequate training of radiation oncology inhabitants, associated with insufficient upkeep of brachytherapy skills amid practicing radiation oncologists. Correspondingly, despite evidence displaying its effectiveness in the management of prostate cancer at every stage of disease, tendencies representing the reduced application of brachytherapy for cervical cancer have been witnessed in the former decade. The decreasing use of brachytherapy is expected secondary to several societal and economic influences, comprising the reduction in prostate specific antigen screening, a better prominence on active investigation for suitable patients, growing usage of robotic prostatectomy and the superior sophistication of exterior beam technologies.